The CEO's large, concentrated open-market purchase at an average price near $105 is a high-conviction signal. With 80% analyst bullishness and strong institutional accumulation (6 funds doubled positions), this cluster reinforces the bull case. Traders should watch for near-term catalysts (pipeline updates, partnership news) that may have motivated the insider buying. The small director sale by Manhard is likely routine portfolio rebalancing and does not offset the CEO's signal.
Price Chart
Executive Summary
CEO Mark Lappe made a large open-market purchase cluster totaling ~$2.6M across six trades on September 8, 2026, alongside director Douglas Forsyth ($287K) and Jon Faiz Kayyem ($568K) also buying. Director Kimberly Manhard sold a small $116K position over two days. The CEO's conviction buy at prices from $99 to $112 is a strong bullish signal, especially given the $1.7B market cap and the fact that the buys are not part of a 10b5-1 plan. The cluster is amplified by the cross-filing context of insider trades and recent press/agreement filings, per the actuarial verdicts.
Key Financial Metrics
Key Facts
- CEO Mark Lappe purchased 25,000 shares total for ~$2.65M across six open-market trades on September 8, 2026, at prices ranging from $99.29 to $112.28.
- Director Douglas Forsyth purchased 2,500 shares for $287K at $114.65 on September 8.
- Director Jon Faiz Kayyem purchased 5,000 shares for $568K at $113.52 on September 8.
- Director Kimberly Manhard sold 1,000 shares total for ~$115K across two days (Sept 8-9) at ~$115.50 — a trivial amount relative to the CEO's buys.
- Total insider buying in the cluster is ~$3.5M vs. selling of ~$116K, a 30:1 ratio in dollar terms.
- The cluster represents ~0.21% of INBX's $1.7B market cap, which is a modest but notable proportion for a single-week insider buying cluster.
Financial Impact
CEO alone deployed ~$2.65M of personal capital; total insider buying ~$3.5M vs. selling ~$116K
Risk Factors
- The stock trades at ~$115, above the CEO's average buy price of ~$105, suggesting some of the bullish thesis may already be priced in.
- Biotech binary risk (pipeline failure, regulatory setback) remains regardless of insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INBX-1789081595011 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Buy | $90.50 | awaiting T+60 | — | $88.66 (−2.03%) |
Sep 28, 2026 27d ago | Insider Cluster | $104.83 | awaiting T+60 | — | $88.66 (−15.42%) |
Sep 17, 2026 5w ago | Insider Cluster | $109.35 | awaiting T+60 | — | $88.66 (−18.92%) |
Sep 15, 2026 5w ago | Insider Cluster | $101.77 | awaiting T+60 | — | $88.66 (−12.88%) |
Sep 15, 2026 5w ago | 144 | $101.77 | awaiting T+60 | — | $88.66 (−12.88%) |
Sep 14, 2026 5w ago | 144 | $105.61 | awaiting T+60 | — | $88.66 (−16.05%) |
Sep 11, 2026 6w ago | 144 | $109.27 | awaiting T+60 | — | $88.66 (−18.86%) |
Sep 10, 2026 6w ago | Insider Cluster | $109.27 | awaiting T+60 | — | $88.66 (−18.86%) |
Sep 8, 2026 6w ago | Insider Cluster | $112.86 | awaiting T+60 | — | $88.66 (−21.44%) |
Sep 8, 2026 6w ago | Insider Buy | $112.86 | awaiting T+60 | — | $88.66 (−21.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers